Search
for

    Research

    5 / 1000+ results
      Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma

      research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

      234 citations , September 2004 in “Clinical cancer research”
      In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.
      Aldesleukin

      research Aldesleukin

      October 2015 in “Elsevier eBooks”
      Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

    Learn

    1 / 801 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

    Community Join

    5 / 146 results